These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21559812)

  • 1. Immune hemolysis after fludarabine-based reduced intensity conditioning and allogeneic PBSC transplantation for CML with minor ABO incompatibility.
    Calixto R; Ostronoff F; Ostronoff M; Sucupira A; Florêncio R; Maior AP; Domingues MC; Chandrasekaran V
    Ann Hematol; 2012 Feb; 91(2):295-7. PubMed ID: 21559812
    [No Abstract]   [Full Text] [Related]  

  • 2. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning.
    Worel N; Greinix HT; Supper V; Leitner G; Mitterbauer M; Rabitsch W; Fischer G; Rosenmayr A; Höcker P; Kalhs P
    Transfusion; 2007 Aug; 47(8):1494-502. PubMed ID: 17655594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
    Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ
    Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.
    Canals C; Muñiz-Díaz E; Martínez C; Martino R; Moreno I; Ramos A; Arilla M; Boto N; Pastoret C; Remacha A; Sierra J; Madoz P
    Transfusion; 2004 Nov; 44(11):1603-11. PubMed ID: 15504166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Massive immune hemolysis after non-myeloablative allogeneic peripheral blood stem cell transplantation with minor ABO-incompatibility.
    Noborio K; Muroi K; Izumi T; Toshima M; Kawano-Yamamoto C; Otsuki T; Nagai T; Komatsu N; Ozawa K
    Leuk Lymphoma; 2003 Feb; 44(2):357-9. PubMed ID: 12688358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful reduced-intensity allogeneic transplantation utilizing a fludarabine-based preparative regimen in a patient with chronic lymphocytic leukaemia and a history of fludarabine-associated autoimmune haemolytic anaemia.
    Ford CD; Asch J; Pulsipher M; Petersen FB
    Br J Haematol; 2004 Aug; 126(4):623-4. PubMed ID: 15287959
    [No Abstract]   [Full Text] [Related]  

  • 7. [Massive hemolysis following allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility].
    Ishiyama M; Iwabe K; Hida M; Okamura T; Yoshinaga K; Hidai H; Kobayashi S; Sameshima Y; Mori N; Teramura M; Masuda M; Motoji T; Mizoguchi H
    Rinsho Ketsueki; 2002 Jun; 43(6):477-81. PubMed ID: 12134705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease.
    Weisser M; Schleuning M; Ledderose G; Rolf B; Schnittger S; Schoch C; Schwerdtfeger R; Kolb HJ
    Bone Marrow Transplant; 2004 Dec; 34(12):1083-8. PubMed ID: 15489879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
    Holowiecki J; Giebel S; Wojnar J; Krawczyk-Kulis M; Markiewicz M; Holowiecka-Goral A; Freund M; Casper J
    Br J Haematol; 2008 Jun; 142(2):284-92. PubMed ID: 18492101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of isohemagglutinin production following minor ABO incompatible unrelated HLA mismatched umbilical cord blood transplantation.
    Snell M; Chau C; Hendrix D; Fox R; Downes KA; Creger R; Meyerson H; Telen MJ; Laughlin MJ; Lazarus HM; Yomtovian R
    Bone Marrow Transplant; 2006 Jul; 38(2):135-40. PubMed ID: 16751785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
    Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
    Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
    Okumura H; Yamaguchi M; Kotani T; Sugimori N; Sugimori C; Ozaki J; Kondo Y; Yamazaki H; Chuhjo T; Takami A; Ueda M; Ohtake S; Nakao S
    Eur J Haematol; 2007 Feb; 78(2):157-60. PubMed ID: 17313562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfusion-free reduced-intensity conditioned allogeneic stem cell transplantation in a Jehovah's witness.
    Zenz T; Döhner H; Bunjes D
    Bone Marrow Transplant; 2003 Aug; 32(4):437-8. PubMed ID: 12900782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia.
    Krejci M; Mayer J; Doubek M; Brychtova Y; Pospisil Z; Racil Z; Dvorakova D; Lengerova M; Horky O; Koristek Z; Dolezal T; Vorlicek J
    Bone Marrow Transplant; 2006 Oct; 38(7):483-91. PubMed ID: 16980996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
    Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
    Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation.
    Stussi G; Muntwyler J; Passweg JR; Seebach L; Schanz U; Gmür J; Gratwohl A; Seebach JD
    Bone Marrow Transplant; 2002 Jul; 30(2):87-93. PubMed ID: 12132047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of pure red cell aplasia with a single low dose of rituximab in two patients after major ABO incompatible peripheral blood allogeneic stem cell transplantation.
    Zhidong W; Hongmin Y; Hengxiang W
    Transfus Med; 2012 Aug; 22(4):302-4. PubMed ID: 22540210
    [No Abstract]   [Full Text] [Related]  

  • 20. Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components.
    Rowley SD; Liang PS; Ulz L
    Bone Marrow Transplant; 2000 Oct; 26(7):749-57. PubMed ID: 11042656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.